bioRxiv (Cold Spring Harbor Laboratory) · 2018 · 10 citations · 44 references
Veterinary MedicineGynecologyOncologyMetastasisMolecular OncologyNeoplasiaEpithelial TumorsMalignant NeoplasmsOncogenic Signaling PathwaysOvarian CancerOvarian NeoplasiaOvarian PathologyCancer OrganoidsMalignant Ovarian NeoplasmsOncogenic TransformationOrganoidsOvarian Cancer MetastasisSerous Tubal Intraepithelial CarcinomaSurface EpitheliumTumor Organoid Models
ABSTRACT The cell-of-origin of high grade serous ovarian carcinoma (HGSOC) remains controversial, with fallopian tube epithelium (FTE) and ovarian surface epithelium (OSE) each suggested as candidates. Here, by using genetically engineered mouse models and novel organoid systems, we assessed the tumor-forming capacity and properties of FTE and OSE harboring the same oncogenic abnormalities. Combined RB family inactivation (via T121 expression) and Tp53 mutation in Pax8+ FTE caused transformation to Serous Tubal Intraepithelial Carcinoma (STIC), which rapidly metastasized to the ovarian surface. This mouse model was recapitulated by FTE organoids, which, upon orthotopic injection, generated widely metastatic HGSOC. The same genetic lesions in Lgr5+ OSE cells or organoids also caused metastatic HGSOC, although with longer latency and lower penetrance. Comparative transcriptome analysis was consistent with different human HGSOCs arising from FTE and OSE. Furthermore, FTE- and OSE-derived organoids showed differential sensitivity to HGSOC chemotherapeutics. Our results comport with a dualistic origin for HGSOC and suggest the cell-of-origin could influence therapeutic response. SIGNIFICANCE The cell-of-origin for high grade serous ovarian carcinoma (HGSOC) has been controversial. By generating novel GEMMs and organoid models with the same oncogenic defects, we demonstrate that HGSOC can originate from either fallopian tube epithelium (FTE) or ovarian surface epithelium (OSE). Importantly, FTE- and OSE-derived tumors differ significantly in biologic properties.
44
Integrated genomic analyses of ovarian carcinoma
Debra Bell, Andrew Berchuck, Narciso Olvera et al. · Nature · 2011 · 8.2K citations · Full text
A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity
Norman Sachs, Joep de Ligt, Oded Kopper et al. · Cell · 2017 · 2K citations · Full text
Medicine, Cancer Biology, Oncology +12
Ovarian Cancer Development and Metastasis
Ernst Lengyel · American Journal Of Pathology · 2010 · 1.7K citations · Full text
Medicine, Cancer Biology, Oncology +12
Prophylactic Oophorectomy in Carriers of<i>BRCA1</i>or<i>BRCA2</i>Mutations
Timothy R. Rebbeck, Henry T. Lynch, Susan L. Neuhausen et al. · New England Journal of Medicine · 2002 · 1.5K citations
Medicine, Gynecology, Surgery +16